Voluntis S.A. (ENXTPA:ALVTX) and its main shareholders announced that they have entered into exclusive negotiations with AptarGroup, Inc. (NYSE:ATR) with respect to a potential acquisition of all outstanding shares of Voluntis by Aptar. This acquisition would complement Aptar's existing digital health portfolio of connected devices by adding digital therapeutic solutions and broadening its digital health services across multiple chronic conditions and diseases. With the acquisition of Voluntis, a pioneer in digital therapeutics, Aptar would have immediate access to an established proprietary platform and algorithms that will drive future digital solutions provided to pharmaceutical and biotech customers as well as other healthcare stakeholders including payers and providers.